Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mylan's Generic EpiPen: A Good PR Move, But Risks Alienating Payers

Executive Summary

Mylan's plan to provide a generic version of its emergency allergic reaction drug EpiPen may be a good PR move, but it may alienate payers further. It also has spurred new skepticism about the company's pricing practices.

You may also be interested in...



Express Scripts Pushing Manufacturers To Lower List Prices By Offering Cheaper Brand Alternatives

Companies should introduce same drug under new NDC at lower list price to overcome difficulties of reducing list prices on existing brands, PBM says.

Investors Relieved As Mylan Settlement Avoids Investigation

Mylan shares rallied on Oct. 7 following the company’s late-day Oct. 10 announcement that it agreed to settlement terms with the Department of Justice related to Epipen rebates for Medicaid prescriptions, but separate investigations and competition are looming.

How Many Pricing Hearings Add Up To Action On Pricing Transparency?

Mylan’s discussion of how the drug supply chain absorbs pricing for EpiPen raised more questions than it answered during a House Oversight Committee hearing

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC097197

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel